CN104189955A - Degradable endocranium repair stent compounded by human amniotic membrane and bull dorsal aponeurosis and preparation method of repair stent - Google Patents
Degradable endocranium repair stent compounded by human amniotic membrane and bull dorsal aponeurosis and preparation method of repair stent Download PDFInfo
- Publication number
- CN104189955A CN104189955A CN201410389662.2A CN201410389662A CN104189955A CN 104189955 A CN104189955 A CN 104189955A CN 201410389662 A CN201410389662 A CN 201410389662A CN 104189955 A CN104189955 A CN 104189955A
- Authority
- CN
- China
- Prior art keywords
- tendon
- amniotic membrane
- sheet
- preparation
- people
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001691 amnion Anatomy 0.000 title claims abstract description 112
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 230000008439 repair process Effects 0.000 title abstract description 13
- 244000309464 bull Species 0.000 title abstract 10
- 102000008186 Collagen Human genes 0.000 claims abstract description 26
- 108010035532 Collagen Proteins 0.000 claims abstract description 26
- 229920001436 collagen Polymers 0.000 claims abstract description 22
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 21
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 21
- 210000004379 membrane Anatomy 0.000 claims abstract description 13
- 239000012528 membrane Substances 0.000 claims abstract description 13
- 238000007710 freezing Methods 0.000 claims abstract description 5
- 230000008014 freezing Effects 0.000 claims abstract description 5
- 210000002435 tendon Anatomy 0.000 claims description 132
- 210000001951 dura mater Anatomy 0.000 claims description 51
- 150000001875 compounds Chemical class 0.000 claims description 36
- 239000000463 material Substances 0.000 claims description 30
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000835 fiber Substances 0.000 claims description 8
- 230000000717 retained effect Effects 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 239000004744 fabric Substances 0.000 claims description 7
- 238000004321 preservation Methods 0.000 claims description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 6
- 101710163270 Nuclease Proteins 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000003431 cross linking reagent Substances 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 210000005081 epithelial layer Anatomy 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 230000007062 hydrolysis Effects 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- -1 hydroxy fatty acid Chemical class 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 229920002160 Celluloid Polymers 0.000 claims description 3
- 239000004971 Cross linker Substances 0.000 claims description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 102000006382 Ribonucleases Human genes 0.000 claims description 3
- 108010083644 Ribonucleases Proteins 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 3
- 239000001569 carbon dioxide Substances 0.000 claims description 3
- 230000009514 concussion Effects 0.000 claims description 3
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 210000002808 connective tissue Anatomy 0.000 claims description 2
- 239000000155 melt Substances 0.000 claims description 2
- 230000006870 function Effects 0.000 abstract description 6
- 102000039446 nucleic acids Human genes 0.000 abstract description 5
- 108020004707 nucleic acids Proteins 0.000 abstract description 5
- 150000007523 nucleic acids Chemical class 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 4
- 230000005847 immunogenicity Effects 0.000 abstract description 3
- 238000003672 processing method Methods 0.000 abstract description 3
- 230000004071 biological effect Effects 0.000 abstract description 2
- 238000004132 cross linking Methods 0.000 abstract 3
- 238000001035 drying Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 13
- 230000002490 cerebral effect Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 10
- 210000002418 meninge Anatomy 0.000 description 8
- 230000007547 defect Effects 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 241001269524 Dura Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000004676 glycans Polymers 0.000 description 4
- 210000003516 pericardium Anatomy 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000009958 sewing Methods 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000003195 fascia Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000006735 Periostitis Diseases 0.000 description 2
- 241000282894 Sus scrofa domesticus Species 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 210000003425 amniotic epithelial cell Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000005065 mining Methods 0.000 description 2
- 210000003460 periosteum Anatomy 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 1
- 208000002403 Encephalocele Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000021945 Tendon injury Diseases 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 239000000515 collagen sponge Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002532 foramen magnum Anatomy 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010010 raising Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 210000001202 rhombencephalon Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides a preparation method of a degradable endocranium repair stent compounded by a human amniotic membrane and bull dorsal aponeurosis. The preparation method comprises the following steps: (1) preparing an amniotic membrane; (2) preparing bull dorsal aponeurosis pieces; and (3) performing non-toxic crosslinking for amniotic membrane and bull dorsal aponeurosis pieces. The endocranium repair stent compounded by a human amniotic membrane and bull dorsal aponeurosis comprises the prepared amniotic membrane and the bull dorsal aponeurosis pieces; the prepared amniotic membrane and the bull dorsal aponeurosis pieces are subjected to non-toxic crosslinking to obtain the endocranium repair stent compounded by a human amniotic membrane and bull dorsal aponeurosis. According to the preparation method, the amniotic membrane processing method meets national standard, and the biological activity function of the amniotic membrane can be remained; the preparation of the bull dorsal aponeurosis pieces is different from the preparation of other collagen membranes, namely, the cell, nucleic acid and other immunogenicity substances can be removed without damaging the structure of the natural bull dorsal aponeurosis collagen, and the mechanical property is remained; in addition, the biosecurity is improved; and the two natural collagen membranes are subjected to non-toxic crosslinking and freezing and drying, and all functions meet the clinical requirements of repair of endocranium.
Description
Technical field
The present invention relates to a kind of duramater reparation support, is a kind of degradable people amniotic membrane and ox back tendon compound duramater reparation support and preparation method specifically.
Background technology
Cerebral dura mater is the important barrier together of protection cerebral tissue, is a thick and tough and tensile duplicature.Dural skin is the periosteum of skull inner face, loosely invests braincap, particularly adheres to more loosely at occipitalia and temples, is called periosteal layer; Internal layer is compared with outer bed thickness and tough and tensile, with spinal dura mater at Foramen magnum place continuous company, be called meninges layer.The factors such as wound, tumor erosion and operation all can cause dura defect, must repair, to prevent that cerebrospinal leak, intracranial infection and cortex adhesion from causing the complication such as epilepsy.
Duramater reparation Clinical Processing mode has two kinds at present: 1. suture type, with artificial dural repairment material (as " meninges bodyguard ", processed by bovine pericardium) directly sew up damaged place, be stitched together with self meninges, the method is applicable to little leak, press the patient of cerebral hernia decompression hindbrain bulging for acute high cranium, sew application difficulty easily injures cerebral tissue in the time sewing up.2. paste formula, directly paste at damaged place with artificial dural repairment material (as collagen protein sponge), clinical existence pastes not tight, and cerebrospinal fluid seepage easily forms the outer hydrops of meninges.
Research shows, each square millimeter of cerebral dura mater of people can bear the tension stress intensity of 37kg left and right, can bear the stitching tension force of various model sutures.Desirable duramater reparation support should comprise following quality factor: (1) has the regeneration and restoration of promotion function; (2) after sewing up, can accomplish to sew up densification waterproof, prevent cerebrospinal fluid seepage, protection cerebral tissue; (3) can stop to transmit potential known or unknown infection; (4) use safety, without rejection, non-toxic reaction, without carcinogenic, teratogenesis; (5) can after generating, cambium be completely absorbed; (6) easily preserve, pre-operative preparation is simple and convenient; (7) material source is convenient; (8) price is relatively moderate.
Wound, tumor corrode and the factor such as operation all can cause dura defect, postoperatively cerebrospinal fluid seepage, intracranial infection and cortex adhesion occur cause the complication such as epilepsy.About meninges repair bibliographical information can trace back to the earliest 1890, experienced from native gold to fascia, the development course by people's corpse meninges to the macromolecule polymer material of xenogenesis fascia tissue and even synthetic.
Mainly contain four classes such as autologous fascia (autologous film material drawn materials Xian ﹑ cause that secondary Chuan Shang ﹑ intensity is poor compared with cerebral dura mater), allogeneic material (corpse cerebral dura mater), foreign material (common bovine pericardium, Cor Sus domestica bag), natural and synthetic material for repairing dural material at present, after front two class substitution material transplanting, effect is relatively good, because source is limited, limit its clinical middle extensive use.Rear two class substitutes are drawn materials conveniently can alleviate the shortage of donor graft materials of the same race to a certain extent effectively.
Recent year is applied more product clinically: Biotype artificial cerebral dura mater---collagen protein sponge, is mainly made after lyophilization by NTx protein gel; Removing antigen heterogeneity biological material after treatment---" meninges bodyguard " (through bovine pericardium products of glutaraldehyde processing) etc., have the trend that becomes main product.But because collagen protein sponge normally becomes collagen gel by animal tendon through acid, alkali or enzyme hydrolysis, become spongy collagen biomembrane through lyophilization again, its sewing properties, mechanical performance are poor, and degradation speed is too fast, can not serve as conventional material generally for dural repair, especially large at dura defect, cerebral can not use the in the situation that of higher." meninges bodyguard " is in preparation process simultaneously, adopt glutaraldehyde tissue management technique removing antigenic while of foreign protein, the a small amount of aldehyde radical constantly occurring in material, introduce residual toxicity, be difficult for thoroughly removing in additional subsequent treatment, although this class toxicity intensity is lower, but the persistent period is very long, almost suitable with the implantation life-span of material, although faint residual toxicity is the not obvious histocompatibility that affects after fibrous connective tissue forms cyst wall, it but block cell to the migration of implanting tissue, be difficult to metabolism and further assimilate implanting tissue, be unfavorable for tissue repair.
Reproducibility reparation is the trend of biomedical development, not only requires material to have good histocompatibility and desirable mechanical property, also will allow autogenous cell to grow into wherein, gradually metabolism patching material be formed with the cambium of function.Current substituted type dural repairment material does not all reach this requirement.
Amniotic membrane, as a kind of natural resources of preciousness, has good biological character, and development prospect is wide.Research shows, people's amniotic epithelial cells has obvious plasticity and multi-lineage potential, under the adjusting of different somatomedin, can be divided into the Various Tissues cells such as liver like cell, cardiac-like muscle cell, neurogliocyte, neuronal cell and islet-like cells, medically have broad application prospects at cell replacement therapy and tissue regeneration.The bioactive substance that contains multiple adjusting cytoactive, promotion damaged tissue healing in amniotic membrane fibre substrate, comprises plurality of enzymes, activated protein, cytokine etc.The buffer action of amnion stroma layer and cytokine profiles, biological activity protein are jointly brought into play protection wound surface, prevent adhesion, suppress local inflammation reaction, are promoted damage field histiocyte to repair the biological actions such as hypertrophy, be a kind of desirable biological restoration timbering material.
The clinical application range of amniotic membrane is in continuous expansion both at home and abroad, not only can rebuild for eye table, can also be used for promoting tendon injury reparation, promote peripheral nerve regeneration reparation, promote periosteum growth and knitting, burns unit, plastic surgery, gynecological, Urology Surgery etc. are rebuild mucosa and skin histology, have also obtained gratifying results in the application in stem-cell research and Tissue Engineering Study field.But independent people's amniotic membrane exists mechanical property not reach the problem of clinical requirement as cerebral dura mater repair materials.
In sum, the defect that prior art exists is:
1. adopt the combination of submucous layer of small intestine (about 0.08mm) and people's amniotic membrane (about 0.05mm), thickness and cerebral dura mater differ larger, sewing properties, the poor requirement that does not reach clinical practice of mechanical performance;
2. on bovine pericardium or Cor Sus domestica peplos, attach one deck and cultivate the autologous vascular endothelial cell or the umbilical cord venous endothelial cell that survive, cultivation, preservation condition and the pre-operative preparation of these living cells are had relatively high expectations, use inconvenience, production technology, production cost and the costs of commodity circulation of product be all corresponding raisings also;
3. collagen sponge is taking animal tendon collagen as raw material, but in its making, collagen protein, after peracid or alkali treatment, partial hydrolysis occurs, and the structure of collagen fiber has a very large change, and its mechanical property is good not as native state;
4. the mechanical property of synthesized polymer material can meet the clinical requirement of duramater reparation, is all not so good as natural macromolecular material but its biology performance comprises regeneration and restoration, biocompatibility etc.
Summary of the invention
The object of the invention is, in order to solve the existing defect of dural repairment material in prior art, provides a kind of degradable people amniotic membrane and ox back tendon compound duramater reparation support and preparation method to solve the problems referred to above.
To achieve these goals, technical scheme of the present invention is as follows:
The preparation method of the compound duramater reparation support of degradable people amniotic membrane and ox back tendon, is characterized in that, comprises the following steps:
(1) prepare amniotic membrane: carry out amniotic membrane by national standard (YZB/ state 0593-2005) and draw materials and prepare;
(2) prepare ox back tendon tendon sheet: fresh ox back tendon production technology water cleaning, the peracetic acid soaking disinfection 1-2hr that is 0.1%-0.5% by concentration, then use washed with de-ionized water; After saline soak 1-2hr with 1%-5%, be placed in the temperature of-20 DEG C--40 DEG C and carry out freezingly, be longitudinally cut into tendon sheet along ox back tendon fiber trend; Tendon sheet is put to-20 DEG C of--40 DEG C of freezing rear taking-ups to be put into the clear water of 20 DEG C-40 DEG C and melts rinse-added, after multigelation like this 2-5 time, comprise with nuclease: the RNase that the DNase that concentration is 100-200U/mL and concentration are 50-150U/mL processes, temperature is 20-45 DEG C, shaking table concussion is after 8-24 hour, to pH6.5-7.5, make ox back tendon tendon sheet through PBS buffer solution for cleaning 3-5 time, put under the environment of 4-8 DEG C cold preservation for subsequent use;
(3) amniotic membrane and ox back tendon tendon sheet is nontoxic crosslinked: by above-mentioned amniotic membrane and ox back tendon collagem membrane after PBS buffer or normal saline infiltrate 5-10 minute, the epithelial layer of amniotic membrane is tiled down, again the above-mentioned ox back tendon tendon sheet of handling well is layered on amniotic membrane, amniotic membrane and ox back tendon tendon sheet are placed in to non-toxic crosslinker, cross-linking agent comprises: molecular weight is at 1500-5000 glycoprotein, the hydroxy fatty acid of carbon number below 30, through 20-60 minute, 25 DEG C-37 DEG C, after the crosslinked bath of PH4.5-7.5, discard solution, and with deionized water rinsing 2-5 time repeatedly, control solid carbon dioxide postlyophilization, packaging, sterilizing, make the compound duramater reparation support of people's amniotic membrane and ox back tendon tendon sheet.
The preparation method of the compound duramater reparation support of above-mentioned degradable people amniotic membrane and ox back tendon, it is characterized in that, in described step (3), ox back tendon tendon sheet comprises two-layer, two-layer ox back tendon tendon sheet intersects and stacks according to the transverse and longitudinal of tendon collagen fabric trend, and then the two-layer ox back tendon tendon sheet of folding is layered on amniotic membrane.
The preparation method of the compound duramater reparation support of above-mentioned degradable people amniotic membrane and ox back tendon, is characterized in that, covers one deck amniotic membrane epithelial layer amniotic membrane upward in described step (3) on ox back tendon tendon sheet again.
The preparation method of the compound duramater reparation support of above-mentioned degradable people amniotic membrane and ox back tendon, is characterized in that, the concentration of the peracetic acid in described step (2) is 0.2%, and includes 5% dehydrated alcohol in the concentration peracetic acid that is 0.2%; The temperature of nuclease is 37 DEG C; By the ox back tendon tendon sheet making, put under the environment of 4 DEG C cold preservation for subsequent use.
The preparation method of the compound duramater reparation support of above-mentioned degradable people amniotic membrane and ox back tendon, is characterized in that, in described step (2), the thickness of tendon sheet is 0.3-0.5mm, and length is: 10-100mm, width is: 10-50mm.
The preparation method of the compound duramater reparation support of above-mentioned degradable people amniotic membrane and ox back tendon, is characterized in that, in described step (3) in the time of tiling amniotic membrane, the celluloid filter paper of place mat 0.45 μ m micropore below amniotic membrane.
The duramater reparation support that degradable people amniotic membrane and ox back tendon are compound, is characterized in that, comprises by the above-mentioned amniotic membrane preparing and ox back tendon tendon sheet, by the nontoxic crosslinked people's amniotic membrane obtaining and the compound duramater reparation support of ox back tendon tendon sheet.
The duramater reparation support that above-mentioned degradable people amniotic membrane and ox back tendon are compound, it is characterized in that, ox back tendon tendon sheet comprises two-layer, and two-layer ox back tendon tendon sheet intersects and stacks according to the transverse and longitudinal of tendon collagen fabric trend, and then the two-layer ox back tendon tendon sheet of folding is layered on amniotic membrane.
The duramater reparation support that above-mentioned degradable people amniotic membrane and ox back tendon are compound, is characterized in that, upper one deck amniotic membrane epithelial layer amniotic membrane upward that covers again of ox back tendon tendon sheet.
Beneficial effect of the present invention is: adopt people's amniotic membrane and ox back tendon tendon sheet through nontoxic crosslinked compound duramater reparation support, amniotic membrane processing method meets national standard, can retain the bioactive functions of amniotic membrane; The preparation of ox back tendon tendon sheet is different from the preparation method of other collagem membranes, has both removed the immunogenic substance such as cell, nucleic acid, fat, does not destroy again the structure of natural ox back tendon collagen, its mechanical property is retained, and biological safety is improved.Two kinds of natural collagem membranes are after nontoxic crosslinked and lyophilization, and its properties meets the clinical requirement of duramater reparation.Specifically comprise: 1, the preparation method of ox back tendon tendon sheet, having adopted height to ooze saline solution soaks and adds multigelation and make cell rupture, destroy nucleic acid material in conjunction with enzyme process again, both the immunogenicity of ox back tendon can be removed by this processing, and the original structure of natural ox back tendon collagen and mechanical property thereof can be retained again as far as possible; 2, the Combined Mining of two kinds of collagem membranes has used nontoxic crosslinked bath to add cryodesiccated method, and the biological safety of product is increased, and preparation method and the permutation and combination method of ox back tendon tendon sheet, make the mechanical property of product of the present invention better; 3, the combination of people's amniotic membrane and ox back key collagem membrane, had both retained the good biology performance of people's amniotic membrane, particularly Regeneration and Repair performance, had increased again the mechanical property of ox back tendon tendon sheet, can meet the clinical demand of dural repairment material.
Brief description of the drawings
Fig. 1 is the structural representation of the embodiment of the present invention 1;
Fig. 2 is the structural representation of the embodiment of the present invention 2;
Fig. 3 is the structural representation of the embodiment of the present invention 3.
Detailed description of the invention
For making that architectural feature of the present invention and effect of reaching are had a better understanding and awareness, coordinate detailed explanation in order to preferred embodiment and accompanying drawing, be described as follows:
The preparation method of the compound duramater reparation support of degradable people amniotic membrane and ox back tendon, comprises the following steps:
(1) prepare amniotic membrane: carry out amniotic membrane by national standard (YZB/ state 0593-2005) and draw materials and prepare; In the making of people's amniotic membrane, can retain amniotic epithelial cells or remove epithelial cell with enzymatic isolation method;
(2) prepare ox back tendon tendon sheet: utilization is freezing and thawing repeatedly, make the cell in material form ice crystal, the salinity of residue cytosol increases and causes the swelling fragmentation of cell, thereby change material and cell surface antigen significantly reduce the antigenicity of biomaterial.Research shows, multigelation desmoenzyme is processed the tendon thin slice of 0.3mm, de-cell effect is good, can there is not disintegrate in collagen, natural three dimensional structure and original mechanical property of tendon collagen fiber are retained largely, hot strength is 17-29MPa (when normal adult clinostatism, cerebrospinal pressure is 0.78～1.76kpa), approximately can retain 90% of green strength.
Concrete mode is: production technology water cleaning for fresh ox back tendon, the peracetic acid soaking disinfection 1-2hr that is 0.1%-0.5% by concentration, then use washed with de-ionized water; After saline soak 1-2hr with 1%-5%, be placed in the temperature of-20 DEG C--40 DEG C and carry out freezingly, be longitudinally cut into tendon sheet along ox back tendon fiber trend; Then just tendon sheet is put-20 DEG C of--40 DEG C of freezing rear taking-ups and is put into the clear water of 20 DEG C-40 DEG C and melt rinse-added, after multigelation like this 2-5 time, comprise with nuclease: the RNase that the DNase that concentration is 100-200U/mL and concentration are 50-150U/mL processes, temperature is 25-40 DEG C, shaking table concussion is after 12-24 hour, to pH6.5-7.5, make ox back tendon tendon sheet through PBS buffer solution for cleaning 3-5 time, put under the environment of 5-8 DEG C cold preservation for subsequent use;
(3) amniotic membrane and ox back tendon tendon sheet is nontoxic crosslinked: by above-mentioned amniotic membrane and ox back tendon collagem membrane after infiltrating 5-10 minute, the epithelial layer of amniotic membrane is tiled down, again the above-mentioned ox back tendon tendon sheet of handling well is layered on amniotic membrane, amniotic membrane and ox back tendon tendon sheet are placed in to non-toxic crosslinker, cross-linking agent comprises: molecular weight is at 1500-5000 glycoprotein, the hydroxy fatty acid of carbon number below 30, through 20-60 minute, 25 DEG C-37 DEG C, after the crosslinked bath of PH4.5-7.5, discard solution, and with deionized water rinsing 2-5 time repeatedly, control solid carbon dioxide postlyophilization, packaging, sterilizing, make the compound duramater reparation support of people's amniotic membrane and ox back tendon tendon sheet.
Two kinds of natural collagen proteins are all extracellular matrix, its surface has glycosaminoglycans, occur with polysaccharide chain form, sugar chain has many free hydroxyls, carboxyl or sulfate, electronegative in electrolyte solution, can attract positive charge, as sodium ion etc., these cationes are again in conjunction with large quantity of moisture, and glycosaminoglycans imbibition, has larger toughness; The hairbrush shape structure of glycosaminoglycans, oozes condition processing through (slightly) height, and part discharges in molecule shrinks in conjunction with water glycosaminoglycans, and hairbrush shape structure is hinged to form and sticks, and makes amniotic membrane and dorsal muscles tendon form mechanical connection; Through bi-functional cross-linking agent (aminoacid, hydroxy fatty acid) effect, polysaccharide and polysaccharide, polysaccharide and collagen protein form O-O or/and the glycosidic bonds such as O-N are covalently bound again.Mechanical bond and covalent bond are passed through lyophilization again, make amniotic membrane and tendon produce highly stable cohering.
Consider that tendon collagen fabric is arranged in parallel, cross directional tensile level is lower than longitudinal anti-tensile level, and cerebral dura mater fiber orientation varied (taking arciform, radial, stringer and diagonal fiber as main), there is multiple directions tension force in clinical suture, in wherein another preferred implementation of the present invention, in step (3), ox back tendon tendon sheet comprises two-layer, two-layer ox back tendon tendon sheet intersects and stacks according to the transverse and longitudinal of tendon collagen fabric trend, and then the two-layer ox back tendon tendon sheet of folding is layered on amniotic membrane; In wherein another preferred implementation of the present invention, in described step (3) at upper one deck amniotic membrane epithelial layer amniotic membrane upward that covers again of ox back tendon tendon sheet.
The concentration of the peracetic acid in step (2) is 0.2%, and includes 5% dehydrated alcohol in the concentration peracetic acid that is 0.2%; The hydrolysis temperature of nuclease is 37 DEG C; By the ox back tendon tendon sheet making, put under the environment of 4 DEG C cold preservation for subsequent use.
In step (2), the thickness of tendon sheet is 0.3-0.5mm, and length is: 10-100mm, width is: 10-50mm.
In step (3) in tiling when amniotic membrane, the celluloid filter paper of place mat 0.45 μ m micropore below amniotic membrane.
The preparation method of the compound duramater reparation support of the degradable people amniotic membrane in the present invention and ox back tendon is with respect to prior art, owing to having used the basic unit of ox back tendon tendon sheet as amniotic membrane, for amniotic membrane provides enough tension force, ensure that it can be applied in duramater reparation.
Embodiment 1:
Referring to Fig. 1, the duramater reparation support that degradable people amniotic membrane and ox back tendon are compound, comprise by the above-mentioned amniotic membrane preparing 100 and ox back tendon tendon sheet 200, the epithelial layer of amniotic membrane 100 is tiled down, again the above-mentioned ox back tendon tendon sheet 200 of handling well is layered on amniotic membrane 100, by the nontoxic crosslinked people's amniotic membrane obtaining and the compound duramater reparation support of ox back tendon tendon sheet.
Embodiment 2:
Referring to Fig. 2, the duramater reparation support that degradable people amniotic membrane and ox back tendon are compound, comprise by the above-mentioned amniotic membrane preparing 100 and ox back tendon tendon sheet 200, ox back tendon tendon sheet 200 comprises two-layer, two-layer ox back tendon tendon sheet 200 intersects and stacks according to the transverse and longitudinal of tendon collagen fabric trend, and then the two-layer ox back tendon tendon sheet 200 of folding is layered on amniotic membrane 100, by the nontoxic crosslinked people's amniotic membrane obtaining and the compound duramater reparation support of ox back tendon tendon sheet.(it is to add one deck amniotic membrane above that Fig. 2 also has a kind of situation again)
Embodiment 3:
Referring to Fig. 3, the duramater reparation support that degradable people amniotic membrane and ox back tendon are compound, comprise by the above-mentioned amniotic membrane preparing 100 and ox back tendon tendon sheet 200, upper one deck amniotic membrane epithelial layer amniotic membrane 100 upward that covers again of ox back tendon tendon sheet 200, by the nontoxic crosslinked people's amniotic membrane obtaining and the compound duramater reparation support of ox back tendon tendon sheet.
Beneficial effect of the present invention is: adopt people's amniotic membrane and ox back tendon tendon sheet through nontoxic crosslinked compound duramater reparation support, amniotic membrane processing method meets national standard, can retain the bioactive functions of amniotic membrane; The preparation of ox back tendon tendon sheet is different from the preparation method of other collagem membranes, has both removed the immunogenic substance such as cell, nucleic acid, does not destroy again the structure of natural ox back tendon collagen, its mechanical property is retained, and biological safety is improved.Two kinds of natural collagem membranes are after nontoxic crosslinked and lyophilization, and its properties meets the clinical requirement of duramater reparation.Specifically comprise: 1, the preparation method of ox back tendon tendon sheet, having adopted height to ooze saline solution soaks and adds multigelation and make cell rupture, destroy nucleic acid material in conjunction with enzyme process again, both the immunogenicity of ox back tendon can be removed by this processing, and the original structure of natural ox back tendon collagen and mechanical property thereof can be retained again as far as possible; 2, the Combined Mining of two kinds of collagem membranes has used nontoxic crosslinked bath to add cryodesiccated method, and the biological safety of product is increased, and preparation method and the permutation and combination method of ox back tendon tendon sheet, make the mechanical property of product of the present invention better; 3, the combination of people's amniotic membrane and ox back key collagem membrane, had both retained the good biology performance of people's amniotic membrane, particularly Regeneration and Repair performance, had increased again the mechanical property of ox back tendon tendon sheet, can meet the clinical demand of dural repairment material.
More than show and described ultimate principle of the present invention, principal character and advantage of the present invention.The technical staff of the industry should understand; the present invention is not restricted to the described embodiments; what in above-described embodiment and description, describe is principle of the present invention; the present invention also has various changes and modifications without departing from the spirit and scope of the present invention, and these changes and improvements all fall in claimed scope of the present invention.The protection domain that the present invention requires is defined by appending claims and equivalent thereof.
Claims (9)
1. the preparation method of the compound duramater reparation support of degradable people amniotic membrane and ox back tendon, is characterized in that, comprises the following steps:
(1) prepare amniotic membrane: carry out amniotic membrane by national standard (YZB/ state 0593-2005) and draw materials and prepare;
(2) prepare ox back tendon tendon sheet: fresh ox back tendon is removed surperficial connective tissue, with production technology water clean, the peracetic acid soaking disinfection 1-2hr that is 0.1%-0.5% by concentration, then use washed with de-ionized water; After saline soak 1-2hr with 1%-5%, be placed in the temperature of-20 DEG C--40 DEG C and carry out freezingly, be longitudinally cut into tendon sheet along ox back tendon fiber trend; Tendon sheet is put to-20 DEG C of--40 DEG C of freezing rear taking-ups to be put into the clear water of 20 DEG C-40 DEG C and melts rinse-added, after multigelation like this 2-5 time, comprise with nuclease: the RNase that the DNase that concentration is 100-200U/mL and concentration are 50-150U/mL processes, temperature is 20-45 DEG C, after shaking table concussion 8-24 hour, to pH6.5-7.5, make ox back tendon tendon sheet through PBS buffer solution for cleaning 3-5 time, retain the natural structure of ox back tendon collagen, put under the environment of 4-8 DEG C cold preservation for subsequent use;
(3) amniotic membrane and ox back tendon tendon sheet is nontoxic crosslinked: by above-mentioned amniotic membrane and ox back tendon collagem membrane after PBS buffer or normal saline infiltrate 5-10 minute, the epithelial layer of amniotic membrane is tiled down, again the above-mentioned ox back tendon tendon sheet of handling well is layered on amniotic membrane, amniotic membrane and ox back tendon tendon sheet are placed in to non-toxic crosslinker, cross-linking agent comprises: molecular weight is at 1500-5000 glycoprotein, the hydroxy fatty acid of carbon number below 30, through 20-60 minute, 25 DEG C-37 DEG C, after the crosslinked bath of PH4.5-7.5, discard solution, and with deionized water rinsing 2-5 time repeatedly, control solid carbon dioxide postlyophilization, packaging, sterilizing, make the compound duramater reparation support of people's amniotic membrane and ox back tendon tendon sheet.
2. the preparation method of the compound duramater reparation support of degradable people amniotic membrane according to claim 1 and ox back tendon, it is characterized in that, in described step (3), ox back tendon tendon sheet comprises two-layer, two-layer ox back tendon tendon sheet intersects and stacks according to the transverse and longitudinal of tendon collagen fabric trend, and then the two-layer ox back tendon tendon sheet of folding is layered on amniotic membrane.
3. the preparation method of the compound duramater reparation support of degradable people amniotic membrane according to claim 1 and ox back tendon, is characterized in that, covers one deck amniotic membrane epithelial layer amniotic membrane upward in described step (3) on ox back tendon tendon sheet again.
4. according to the preparation method of the degradable people amniotic membrane described in claim 2 or 3 and the compound duramater reparation support of ox back tendon, it is characterized in that, the concentration of the peracetic acid in described step (2) is 0.2%, and includes 5% dehydrated alcohol in the concentration peracetic acid that is 0.2%; The hydrolysis temperature of nuclease is 37 DEG C; By the ox back tendon tendon sheet making, put under the environment of 4 DEG C cold preservation for subsequent use.
5. the preparation method of the compound duramater reparation support of degradable people amniotic membrane according to claim 4 and ox back tendon, it is characterized in that, in described step (2), tendon sheet has retained the natural structure of ox back tendon collagen, its thickness is 0.3-0.5mm, length is: 10-100mm, width is: 10-50mm.
6. the preparation method of the compound duramater reparation support of degradable people amniotic membrane according to claim 5 and ox back tendon, it is characterized in that, in described step (3) in tiling when amniotic membrane, the celluloid filter paper of place mat 0.45 μ m micropore below amniotic membrane.
7. the compound duramater reparation support of degradable people amniotic membrane and ox back tendon, is characterized in that, comprises by the above-mentioned amniotic membrane preparing and ox back tendon tendon sheet, by the nontoxic crosslinked people's amniotic membrane obtaining and the compound duramater reparation support of ox back tendon tendon sheet.
8. the compound duramater reparation support of degradable people amniotic membrane according to claim 7 and ox back tendon, it is characterized in that, ox back tendon tendon sheet comprises two-layer, two-layer ox back tendon tendon sheet intersects and stacks according to the transverse and longitudinal of tendon collagen fabric trend, and then the two-layer ox back tendon tendon sheet of folding is layered on amniotic membrane.
9. the compound duramater reparation support of degradable people amniotic membrane according to claim 7 and ox back tendon, is characterized in that, upper one deck amniotic membrane epithelial layer amniotic membrane upward that covers again of ox back tendon tendon sheet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410389662.2A CN104189955B (en) | 2014-08-08 | 2014-08-08 | The duramater reparation support of degradable people's amnion and ox back tendon compound and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410389662.2A CN104189955B (en) | 2014-08-08 | 2014-08-08 | The duramater reparation support of degradable people's amnion and ox back tendon compound and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104189955A true CN104189955A (en) | 2014-12-10 |
| CN104189955B CN104189955B (en) | 2016-06-15 |
Family
ID=52075413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410389662.2A Active CN104189955B (en) | 2014-08-08 | 2014-08-08 | The duramater reparation support of degradable people's amnion and ox back tendon compound and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104189955B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104888275A (en) * | 2015-04-29 | 2015-09-09 | 陕西瑞盛生物科技有限公司 | Construction method of cartilage cell membrane patch |
| CN106474548A (en) * | 2015-08-28 | 2017-03-08 | 北京华信佳音医疗科技发展有限责任公司 | A kind of biological induction type artificial dura mater and preparation method thereof |
| CN106901866A (en) * | 2015-12-22 | 2017-06-30 | 上海典范医疗科技有限公司 | Compound dural patch for preventing adhesion and preparation method thereof |
| CN111330079A (en) * | 2020-03-31 | 2020-06-26 | 江苏白衣缘生物工程有限公司 | Artificial dura mater composite patch |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103263694A (en) * | 2013-05-14 | 2013-08-28 | 北京华信佳音医疗科技发展有限责任公司 | Collagen-based dura and preparation method thereof |
| CN103357068A (en) * | 2012-04-10 | 2013-10-23 | 成都达普医疗器械有限公司 | Novel biological endocranium patch |
| CN103656749A (en) * | 2013-12-10 | 2014-03-26 | 北华大学 | Composite degradable antibacterial artificial cerebral dura mater and preparation method thereof |
| US20140186461A1 (en) * | 2012-09-10 | 2014-07-03 | Alpha Tissue, Inc. | Human Amniotic Membrane Lyophilized Grafts |
-
2014
- 2014-08-08 CN CN201410389662.2A patent/CN104189955B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103357068A (en) * | 2012-04-10 | 2013-10-23 | 成都达普医疗器械有限公司 | Novel biological endocranium patch |
| US20140186461A1 (en) * | 2012-09-10 | 2014-07-03 | Alpha Tissue, Inc. | Human Amniotic Membrane Lyophilized Grafts |
| CN103263694A (en) * | 2013-05-14 | 2013-08-28 | 北京华信佳音医疗科技发展有限责任公司 | Collagen-based dura and preparation method thereof |
| CN103656749A (en) * | 2013-12-10 | 2014-03-26 | 北华大学 | Composite degradable antibacterial artificial cerebral dura mater and preparation method thereof |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104888275A (en) * | 2015-04-29 | 2015-09-09 | 陕西瑞盛生物科技有限公司 | Construction method of cartilage cell membrane patch |
| CN104888275B (en) * | 2015-04-29 | 2017-07-07 | 陕西瑞盛生物科技有限公司 | A kind of construction method of cartilage cell's diaphragm |
| CN106474548A (en) * | 2015-08-28 | 2017-03-08 | 北京华信佳音医疗科技发展有限责任公司 | A kind of biological induction type artificial dura mater and preparation method thereof |
| CN106474548B (en) * | 2015-08-28 | 2020-01-21 | 北京华信佳音医疗科技发展有限责任公司 | Biological induction type artificial dura mater and preparation method thereof |
| CN106901866A (en) * | 2015-12-22 | 2017-06-30 | 上海典范医疗科技有限公司 | Compound dural patch for preventing adhesion and preparation method thereof |
| CN111330079A (en) * | 2020-03-31 | 2020-06-26 | 江苏白衣缘生物工程有限公司 | Artificial dura mater composite patch |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104189955B (en) | 2016-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10426868B2 (en) | Method for preparing an animal decellularized tissue matrix material and a decellularized tissue matrix material prepared thereby | |
| US20180296317A1 (en) | Sheet tissue products | |
| CN104144715B (en) | The manufacture method of collagen structure body and collagen structure body | |
| US20180216062A1 (en) | Method for Enzymatic Treatment of Tissue Products | |
| CN105935454A (en) | Decellularized matrix-source tissue engineering scaffold and preparation method and application thereof | |
| CN102198292B (en) | Scaffolds of umbilical cord decellularized Wharton jelly for tissue engineering and preparation method thereof | |
| CN104353111B (en) | A kind of bioprosthetic material for abdominal-wall defect and preparation method thereof | |
| CN101366979B (en) | Tissue patch and preparation method thereof | |
| CN103491986A (en) | Method for enzymatic treatment of tissue products | |
| CN109331229A (en) | A kind of medical bio line, medical bio repair mesh and preparation method thereof | |
| CN102188747A (en) | Compound tissue engineering scaffold containing PLGA (poly(lactic-co-glycolic acid) strengthening net, and preparation method and application thereof | |
| US20190015457A1 (en) | Elastic tissue matrix derived hydrogel | |
| CN101690829B (en) | Method for preparing re-cellularized biological valve material | |
| CN104189955B (en) | The duramater reparation support of degradable people's amnion and ox back tendon compound and preparation method | |
| CA2954191A1 (en) | Methods for selection of age-appropriate tissues | |
| Chen et al. | Hyaluronic acid-based biphasic scaffold with layer-specific induction capacity for osteochondral defect regeneration | |
| CN105999405A (en) | Absorbable fundal mesh composite and preparation method thereof | |
| KR101859654B1 (en) | Cell scaffold including collagen and decellularized extraceulluar matrix and artificial cornea sheet | |
| CN106256384A (en) | A kind of biological sticking patch and preparation method | |
| CN104130437B (en) | A kind of hard brain/spinal meninges biology patching material and its preparation method and application | |
| CN110452413B (en) | Collagen cross-linking agent composition and application thereof | |
| CN100402097C (en) | Skin wound repairing agar/collagen dressing and its prepn and application | |
| CN109758261A (en) | A kind of solid tendon biological sticking patch and its preparation method and application | |
| JP3686068B2 (en) | Separation and decellularization method of skin, decellularized dermal matrix and production method thereof, and composite cultured skin using decellularized dermal matrix | |
| CN210698333U (en) | Biological mesh for repairing soft tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANGXI RUIJI BIO-ENGINEERING TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: MIAO JIUCHANG Effective date: 20150619 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20150619 Address after: 330029 Nanchang, Jiangxi Qingshan Lake District on the road, No. 108 Applicant after: Jiangxi Ruiji Bio-Engineering Technology Co., Ltd. Address before: 330029 No. 38 Factory Road, East Lake District, Jiangxi, Nanchang Applicant before: Miao Jiuchang |
|
| CB02 | Change of applicant information |
Address after: 330000 No. 498, special road, hi tech Development Zone, Jiangxi, Nanchang Applicant after: JIANGXI RUIJI BIO-ENGINEERING TECHNOLOGY CO., LTD. Address before: 330029 Nanchang, Jiangxi Qingshan Lake District on the road, No. 108 Applicant before: Jiangxi Ruiji Bio-Engineering Technology Co., Ltd. |
|
| COR | Change of bibliographic data | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |